1 JANUARY – 30 JUNE 2023
Continued strong growth
NET SALES
EBITA
EARNINGS GROWTH
EBITA R12 MONTHS
P/WC
Demand is developing positively in all areas
AddLife's subsidiaries have strong market positions in growing niches, which is clearly reflected in the company's net sales growth of 14% in the second quarter. Operating profit (EBITA) increased by 3% compared with the previous year, driven primarily by higher net sales growth, and the EBITA margin was 10.4%. In summary, I can conclude that AddLife's companies have strong market positions in well-chosen niches where the conditions for continued profitable growth are good.
A leading player in Life Science
AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.
